Restarting Antidepressants During Pregnancy Linked to Missed Prenatal Ultrasounds

Antidepressant Adherence and Perinatal Care Engagement

Major depressive disorder is a prevalent and debilitating condition that frequently complicates the perinatal period [1]. While antidepressant monotherapy demonstrates stable efficacy over long-term treatment [2], many pregnant women discontinue these medications due to concerns regarding fetal exposure. However, systematic reviews suggest that many adverse neurodevelopmental and physical outcomes previously attributed to in utero exposure are likely driven by the underlying maternal psychiatric disorder rather than the medication itself [3]. Clinical practice guidelines for managing depression emphasize the importance of maintaining stable treatment to prevent relapse and ensure maternal well-being [4]. Despite these recommendations, the relationship between specific medication adherence patterns and a patient's engagement with essential obstetric screenings remains poorly understood. This study examines how shifts in antidepressant use correlate with the utilization of routine perinatal healthcare, providing clinicians with identifiable markers for patients at risk of disengaging from necessary care.

Mapping Medication Patterns in a Large Perinatal Cohort

The researchers conducted a retrospective cohort study utilizing health insurance data from Switzerland spanning the years 2010 to 2019. The total sample size consisted of 69,938 pregnancies that resulted in delivery. To ensure a comprehensive longitudinal view of healthcare utilization and medication adherence, the study required participants to have continuous insurance coverage during four pre-pregnancy trimesters (designated as T-4 to T-1), the three trimesters of pregnancy (T1 to T3), and a 90 day postpartum period. This tracking period allowed the authors to establish a clear baseline of medication use for a full year prior to conception and follow the clinical trajectory through the immediate postnatal phase. Within this population, the researchers identified an exposed group of women who were dispensed antidepressants and categorized their usage into four distinct clinical patterns. These patterns included continuation of the medication throughout the pregnancy, discontinuation at the start of the first trimester (T1), early discontinuation occurring during the final pre-pregnancy trimester (T-1), and a restart of the medication at some point before delivery after an initial period of cessation. This exposed group was compared against a control group consisting of pregnancies where no psychoactive medications were used. A notable limitation of the study design is that diagnoses of mental disorders were unmeasured in the study population, meaning the researchers relied on medication dispensation records as a proxy for the presence and management of affective disorders. This distinction is important for clinicians to consider, as the severity of the underlying psychiatric condition could not be directly adjusted for in the primary analysis, though the act of seeking a prescription remains a strong indicator of clinical need.

Quantifying Discontinuation and Resumption Rates

The researchers identified a specific cohort of 1,430 pregnancies where antidepressants were dispensed during the final pre-pregnancy trimester, a period designated as T-1. This group served as the primary population for analyzing how medication adherence shifts during the transition to parenthood. The data revealed that the majority of these women ceased pharmacotherapy early in the gestational process. Specifically, 728 women discontinued antidepressants before the first trimester (T1), while another 300 women discontinued antidepressants after the first trimester (T1). These figures indicate that nearly 72 percent of women who were on a stable medication regimen immediately prior to conception stopped their treatment by the end of the first three months of pregnancy. In contrast to the high rates of cessation, a smaller subset of 267 women continued antidepressants throughout the entire study period, maintaining their prescriptions from the pre-conception phase through delivery. However, the most clinically significant finding involved a group of 135 women who restarted antidepressants before delivery after an initial period of discontinuation. For the practicing physician, this pattern of resumption often signals a relapse or exacerbation of affective symptoms that were no longer manageable without intervention. This specific group of 135 women became the focal point of the findings, as the act of restarting medication was more strongly associated with gaps in prenatal care than either continuous use or permanent discontinuation, suggesting that clinical instability may be a primary driver of healthcare disengagement.

Impact on Routine Prenatal and Postnatal Screenings

The researchers evaluated two key metrics of healthcare engagement to determine how medication patterns influenced clinical follow-up: the foregone routine prenatal ultrasound served as the primary outcome, while the foregone postnatal examination was analyzed as the secondary outcome. These screenings represent critical touchpoints for identifying fetal anomalies and managing maternal recovery, yet the data revealed significant gaps in attendance among women using antidepressants. When comparing the broad cohorts, 18.6 percent of the antidepressant-exposed group forewent prenatal ultrasound, whereas only 13.2 percent of the comparison group (those with no psychoactive medication use) missed this screening. This trend of decreased engagement extended into the postpartum period, with 26.6 percent of the antidepressant-exposed group foregoing the postnatal examination compared to 21.4 percent in the comparison group. To ensure the robustness of these findings, the authors employed generalized estimating equation models (a statistical framework that accounts for correlations within data, such as when a single woman contributes multiple pregnancies to a dataset). This analysis adjusted for several potential confounders, including maternal age, the specific year of the pregnancy, and the individual identity of the women. The most pronounced risk was identified in the subgroup of 135 women who resumed medication after an initial cessation. In this restart group, 77.0 percent of women forewent their prenatal ultrasound, a figure that stands in sharp contrast to the 13.3 percent missed rate observed across the entire study sample. This resulted in an adjusted odds ratio of 22.43 (95% CI = 15.00 to 33.53, p < .001), suggesting that the clinical instability or symptom recurrence that necessitates restarting an antidepressant is a powerful predictor of missed routine prenatal care.

The High Risk of Care Gaps in the Restart Group

The most striking finding of the study centered on the subgroup of women who resumed antidepressant therapy after an initial period of cessation. Among the four medication patterns analyzed, restarting antidepressants was the only pattern significantly associated with foregone prenatal ultrasound. This specific clinical trajectory appears to serve as a potent marker for healthcare disengagement. While the overall sample of 69,938 pregnancies showed a baseline rate of 13.3 percent for missed ultrasounds, the figures for the restart group were markedly higher. Specifically, 77.0 percent of women in the restart group forewent their routine prenatal ultrasound, representing a substantial departure from standard obstetric care protocols. Statistical analysis using generalized estimating equation models confirmed the magnitude of this association. The researchers calculated an adjusted odds ratio of 22.43 for foregone ultrasound in the restart group, with a 95 percent confidence interval ranging from 15.00 to 33.53 (p < .001). This 22-fold increase in the odds of missing a critical screening suggests that the clinical circumstances leading to a medication restart, such as a relapse of depressive or anxious symptoms, may simultaneously impair a patient's ability to attend scheduled appointments. For the practicing clinician, these data indicate that the timing of antidepressant discontinuation and subsequent resumption is a critical indicator of potential gaps in prenatal monitoring. The stark contrast between the 77.0 percent missed rate in the restart group and the 13.3 percent rate in the entire sample underscores the need for targeted outreach and integrated mental health support when a pregnant patient requires a re-initiation of pharmacotherapy.

References

1. Howard DM, Adams MJ, Clarke T, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019. doi:10.1038/s41593-018-0326-7

2. Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C. Long-Term Acute-Phase Treatment With Antidepressants, 8 Weeks and Beyond: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials.. The Journal of clinical psychiatry. 2018. doi:10.4088/JCP.15r10545

3. Rommel A, Bergink V, Liu X, Munk-Olsen T, Molenaar NM. Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review.. The Journal of clinical psychiatry. 2020. doi:10.4088/JCP.19r12965

4. Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. European Spine Journal. 2018. doi:10.1007/s00586-018-5673-2